Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesTransplantAetna hematopoietic cell transplant Coverage | Ope…
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    CurrentAetnaPolicy 0640

    Hematopoietic Cell Transplantation for Selected Leukemias

    Customize your policy alerts

    Sign up for Aetna Policy 0640 alerts

    Get alerted when Policy 0640 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Medical necessity and coverage criteria for allogeneic and autologous hematopoietic cell transplantation (including reduced-intensity conditioning) for selected leukemias, and interventions considered experimental/investigational. Applies to Aetna members and providers requesting transplant-related services.

    Policy Summary
    PayerAetna
    PolicyHematopoietic Cell Transplantation for Selected Leukemias
    Policy CodePolicy 0640
    Change TypeNo material clinical or coverage changes
    Effective DateAug 20, 2002
    Last ReviewMar 5, 2024
    Next Review DateJul 11, 2024
    Key ActionObtain prior authorization for listed transplant-related codes and document that the member meets the transplanting institution’s selection criteria (remission status, donor availability, organ function, and ability to tolerate procedure).
    SourceLink
    11listed indications
    7experimental items
    nationalscope
    03/05/2024last review

    Coverage Criteria for Hematopoietic Cell Transplantation

    Medically Necessary Interventions

    Aetna considers the following interventions medically necessary when members meet the transplanting institution's selection criteria (or, absent such criteria, when Aetna's listed indications are met):

    Allogeneic HCT for ALL: Allogeneic hematopoietic cell transplantation for treatment of acute lymphocytic leukemia (ALL)meets transplanting institution's selection criteria or, absent that, not in refractory relapse (unresponsive to >=3 months of adequate chemotherapy)

    Includes ablative and non-myeloablative when selection criteria met

    Non-myeloablative allogeneic HCT for ALL: Non-myeloablative (mini-allograft/reduced-intensity) allogeneic HCT is medically necessary for treatment of ALL for members with no persistent disease who meet selection criteriano persistent disease

    Persons with persistent disease should not be candidates

    Autologous HCT for AML:

    Candidate Selection and Contraindications

    Candidate selection nodes

    Candidate requirements referenced in policy (must meet transplanting institution's selection criteria or specific Aetna‑listed indications):

    Fitness and organ function: Members must be physically fit and have adequate organ function for allo‑HCTadequate organ function and fitness

    Documented by transplanting center

    Donor availability: Suitable HLA‑compatible, matched or haploidentical donor availability is required for certain indications (e.g., CMML/JMML, Richter syndrome)donor availability
    Remission status for certain transplants: For non‑myeloablative allogeneic HCT in ALL, members should have no persistent disease; autologous HCT for AML generally used when responsive to intensified induction chemotherapy or in remission

    Pre-Transplant and Donor Evaluation Requirements

    Prior Authorization

    Prior Authorization Required

    Prior authorization is required for hematopoietic cell transplantation (HCT) procedures and related transplant evaluation services. Authorization decisions may be donor- and risk-stratified; providers should request authorization that reflects the planned allogeneic versus autologous HCT, donor type, and anticipated conditioning intensity.

    • Prior authorization required for transplant procedure codes (submit appropriate CPT/HCPCS and facility codes)
    • Donor- and risk-stratified prior authorization: indicate donor type (matched related, matched unrelated, haploidentical, cord blood) and patient risk factors
    Documentation Required

    Documentation Expectations and Pre-Transplant Disease/MRD Documentation

    Documentation must demonstrate disease status, prior therapies, response to therapy, and pre-transplant risk assessment. Include explicit documentation of remission status (CR/CRi), molecular minimal residual disease (MRD) testing results when applicable (for example, PML-RARα RT-PCR for APL, BCR-ABL MRD for Ph+ ALL), and response to CAR-T or TKI therapy if relevant.

    Provider Actions, Prior Authorization, and Documentation

    Covered CPT CodesCPTCovered
    38205Blood-derived hematopoietic cell harvesting for transplantation, per collection; allogeneic [ablative or non-myeloablative]
    38206-38215Transplant preparation procedures
    38230Bone marrow harvesting for transplantation; allogeneic
    38232Bone marrow harvesting for transplantation; autologous
    38240Hematopoietic progenitor cell (HPC); allogeneic transplantation per donor
    38241Hematopoietic progenitor cell (HPC); autologous transplantation
    38242Allogeneic lymphocyte infusions
    86813HLA typing; A, B or C multiple antigens
    86817HLA typing; DR/DQ, multiple antigens
    86821Lymphocyte culture, mixed (MCL)
    Not covered / experimental CPTCPTNot Covered
    0251UHepcidin-25, enzyme-linked immunosorbent assay (ELISA), serum or plasma
    Covered HCPCS CodesHCPCSCovered
    S2150Bone marrow or blood-derived stem cells (peripheral or umbilical), allogeneic or autologous, harvesting, transplantation, and related complications; including: pheresis and cell preparation/storage; marrow ablative therapy; drugs, supplies, hospitalization with outpatient follow-up; medical/surgical, diagnostic, emergency services, and rehabilitative services; and the number of days of pre- and post-transplant care in the global definition.
    Covered ICD-10 CodesICD-10Covered
    C91.00-C91.02Acute lymphoblastic leukemia [ALL] [not covered for autologous transplantation]
    C91.10-C91.12Chronic lymphocytic leukemia of B-cell type [Richter syndrome (RS)]
    C92.00-C92.02Acute myeloblastic leukemia [not covered for repeat autologous transplantation]
    C92.40-C92.42Acute promyelocytic leukemia
    C92.50-C92.52Acute myelomonocytic leukemia
    C92.60-C92.62Acute myeloid leukemia with 11q23-abnormality
    C92.A0-C92.A2Acute myeloid leukemia with multilineage dysplasia
    C93.00-C93.92Monocytic leukemia [CMML/JMML]
    C94.20-C94.22Acute megakaryoblastic leukemia

    Coding — CPT, HCPCS, and ICD-10

    Covered CPT CodesCPTCovered
    38205Blood-derived hematopoietic cell harvesting for transplantation, per collection; allogeneic [ablative or non-myeloablative]
    38206-38215Transplant preparation procedures
    38230Bone marrow harvesting for transplantation; allogeneic
    38232Bone marrow harvesting for transplantation; autologous
    38240Hematopoietic progenitor cell (HPC); allogeneic transplantation per donor
    38241Hematopoietic progenitor cell (HPC); autologous transplantation
    38242Allogeneic lymphocyte infusions
    86813HLA typing; A, B or C multiple antigens
    86817HLA typing; DR/DQ, multiple antigens
    86821Lymphocyte culture, mixed (MCL)
    Not covered / experimental CPTCPTNot Covered
    0251UHepcidin-25, enzyme-linked immunosorbent assay (ELISA), serum or plasma
    Covered HCPCS CodesHCPCSCovered
    S2150Bone marrow or blood-derived stem cells (peripheral or umbilical), allogeneic or autologous, harvesting, transplantation, and related complications; including: pheresis and cell preparation/storage; marrow ablative therapy; drugs, supplies, hospitalization with outpatient follow-up; medical/surgical, diagnostic, emergency services, and rehabilitative services; and the number of days of pre- and post-transplant care in the global definition.
    Covered ICD-10 CodesICD-10Covered
    C91.00-C91.02Acute lymphoblastic leukemia [ALL] [not covered for autologous transplantation]
    C91.10-C91.12Chronic lymphocytic leukemia of B-cell type [Richter syndrome (RS)]
    C92.00-C92.02Acute myeloblastic leukemia [not covered for repeat autologous transplantation]
    C92.40-C92.42Acute promyelocytic leukemia
    C92.50-C92.52Acute myelomonocytic leukemia
    C92.60-C92.62Acute myeloid leukemia with 11q23-abnormality
    C92.A0-C92.A2Acute myeloid leukemia with multilineage dysplasia
    C93.00-C93.92Monocytic leukemia [CMML/JMML]
    C94.20-C94.22Acute megakaryoblastic leukemia

    Post-Transplant Coverage Considerations

    Comprehensive transplant episode (HCPCS S2150)
    HCPCS codeS2150
    ScopeDescribed as covering bone marrow or blood-derived stem cells (peripheral or umbilical), harvesting, transplantation, and related complications; includes pheresis and cell preparation/storage; marrow ablative therapy; drugs, supplies, hospitalization with outpatient follow-up.
    Episode inclusionsEncompasses harvesting, transplantation procedure, related complications, and associated pre- and post-transplant care elements.
    Second allogeneic HSCT
    ConsiderationSecond allogeneic HSCT may be considered as a salvage option for relapse after a first allo-HSCT.
    OutcomesAnalysis of 25 patients: complete remission achieved in most, but relapse occurred in 44% and treatment-related mortality was 32%; 32% alive at median follow-up 18 months.

    Background and Evidence Summary

    Acute lymphocytic leukemia (ALL) is a heterogeneous malignancy of lymphocytic precursors with prognosis that varies by age, immunologic subtype, cytogenetics, and response to induction therapy. Standard management includes multi‑agent chemotherapy and CNS prophylaxis; high‑risk patients may be considered for hematopoietic cell transplantation when selection criteria and disease status warrant.

    Evidence summaries informing transplant coverage decisions

    Duplicate evidence context for Background placement — findings that inform transplant candidacy and expected outcomes (also shown above):

    CMML and JMML evidence: Outcomes in CMML and JMML are heterogeneous; select patients (fewer comorbidities, earlier transplant timing) derive greater benefit though TRM and relapse remain substantial

    Kroger, Kerbauy, Locatelli, Woods

    KIR and donor selection evidence: KIR genotype analyses suggest certain donor KIR B motifs (Cen‑B) associate with lower relapse in AML and may inform donor selection

    Cooley, Bao

    Definitions and Terms

    Primary refractory (definition)
    DefinitionPrimary refractory = leukemia that does not achieve a complete remission after conventional‑dose chemotherapy.
    Context in policyPrimary refractory ALL is explicitly mentioned as medically necessary for allo‑HCT when institution selection criteria are met (except refractory relapse).
    Clinical implicationDistinguishes primary refractory disease from refractory relapse for coverage considerations.
    Mini‑allograft / reduced‑intensity conditioning (definition & appropriateness)
    DefinitionMini‑allograft / non‑myeloablative transplant = reduced‑intensity conditioning allogeneic HSCT appropriate for members with no persistent disease who meet selection criteria.
    Candidate limitationPersons with persistent disease should not be candidates for a mini‑allograft transplant.

    Policy Revision History

    2024-03-05last_reviewLatest

    Policy last reviewed on 03/05/2024; administrative review entry recorded in policy history.

    2002-08-20effective_date

    Policy effective date recorded as 08/20/2002.

    2024-07-11next_review_scheduled

    Next policy review scheduled for 07/11/2024 as noted in document metadata.

    Policy Summary
    PayerAetna
    PolicyHematopoietic Cell Transplantation for Selected Leukemias
    Policy CodePolicy 0640
    Change TypeNo material clinical or coverage changes
    Effective DateAug 20, 2002
    Last ReviewMar 5, 2024
    Next Review DateJul 11, 2024
    Key ActionObtain prior authorization for listed transplant-related codes and document that the member meets the transplanting institution’s selection criteria (remission status, donor availability, organ function, and ability to tolerate procedure).
    SourceLink
    On This Page
    Coverage Criteria for Hematopoietic Cell TransplantationCandidate Selection and ContraindicationsPre-Transplant and Donor Evaluation RequirementsProvider Actions, Prior Authorization, and DocumentationCoding — CPT, HCPCS, and ICD-10Post-Transplant Coverage ConsiderationsBackground and Evidence SummaryDefinitions and TermsPolicy Revision History
    Autologous hematopoietic cell transplantation for treatment of acute myelogenous leukemia (AML)
    meets transplanting institution's selection criteria; in absence of institutional criteria, considered medically necessary for AML for any indication except as first-line treatment

    Examples: first or second remission or relapsed AML if responsive to intensified induction chemotherapy

    Allogeneic HCT for AML: Allogeneic HCT (ablative or mini-allograft) for treatment of AMLmeets transplanting institution's selection criteria or, absent that, any one of: relapsed after prior autologous HCT and medically able to tolerate; poor- to intermediate-risk AML in remission; primary refractory AML

    Includes repeat allo-HCT for graft failure or relapse when selection criteria met

    Allogeneic HCT for CMML/JMML: Allogeneic (ablative or non-myeloablative) HCT for treatment of CMML and JMML when a matched or haploidentical donor is availabledonor available and meets selection criteria

    Repeat allo-HCT allowed for primary graft failure

    Allogeneic HCT for T-cell prolymphocytic leukemia: Allogeneic (ablative or non-myeloablative) HCT for T-cell prolymphocytic leukemia when selection criteria are metmeets institution selection criteria
    HCT as consolidation for APL: Allogeneic or autologous HCT as consolidation therapy for acute promyelocytic leukemia in second or subsequent remissionin second or subsequent remission
    Allogeneic HCT for Richter syndrome: Allogeneic HCT for treatment of Richter syndrome when members are physically fit, have adequate organ function, suitable HLA-compatible donor, and have responded to initial chemoimmunotherapyfitness, organ function, donor availability, response to initial therapy

    Repeat Transplantation

    Conditions when repeat transplantation is considered medically necessary:

    Repeat allogeneic HCT for AML: Repeat allogeneic HCT (ablative or mini-allograft) is medically necessary when first allo-HCT was unsuccessful due to primary graft failure or failure to engraft or for persons who have relapsed after a prior HCTprimary graft failure OR failure to engraft OR relapse after prior HCT

    Must meet transplanting institution's selection criteria

    Repeat allogeneic HCT for CMML/JMML: Repeat allogeneic (ablative or non-myeloablative) HCT due to primary graft failure or failure to engraft for treatment of CMML and JMMLprimary graft failure OR failure to engraft

    KIR Genotyping

    KIR genotyping coverage stance:

    KIR genotyping for donor evaluation in AML/ALL: Killer-cell immunoglobulin-like receptor (KIR) genotyping for evaluating HLA-matched donors for members with AML or ALL undergoing allogeneic HSCT is considered medically necessaryindication: donor evaluation for AML/ALL allogeneic HSCT

    KIR genotyping considered experimental/investigational for all other indications

    General transplantation coverage logic

    Covered when ALL of the following donor-, disease-, or risk-specific conditions are met as supported by the cited evidence:

    General transplantation decision logic

    • Donor availability consideration: Matched related donor preferred; unrelated or alternative donors considered for poor-risk or young patients lacking sibling donors

      Donor-versus-no-donor analyses and guideline recommendations

    Acute lymphocytic leukemia (ALL)

    Covered when ALL of the following are met for ALL:

    ALL in CR1 - donor benefit: Philadelphia chromosome–negative adults with a matched related donor may receive allogeneic HSCT in first complete remission (CR1) because donor availability was associated with improved 5‑year overall survival (53% vs 45%)

    Benefit seen in standard‑risk; high TRM in older/high‑risk patients may abrogate benefit

    ALL alternative approaches: Autologous HSCT did not show superiority to chemotherapy; reduced‑intensity and unrelated‑donor transplants have limited and mixed evidence and should be considered case‑by‑case

    IQWiG assessment noted limited evidence and unclear donor‑type relevance

    Acute myelogenous leukemia (AML)

    Covered when ALL of the following are met for AML:

    AML CR1 - poor/intermediate risk: Patients with poor‑risk cytogenetics (and many with intermediate‑risk) in CR1: allogeneic HSCT is supported by meta‑analyses showing relapse‑free survival and overall survival benefit

    Selection should be based on cytogenetic risk

    AML CR1 - good-risk: Patients with favorable cytogenetics (good‑risk) generally should not receive allo‑HSCT in CR1 because analyses show no OS benefit; non‑transplant consolidation may be optimal

    Auto‑SCT not routinely recommended in CR1

    AML relapse or later remission: Allogeneic HSCT is an option for patients in second or subsequent remission or with relapse, considering donor source and conditioning intensity

    Repeat allo‑HCT and donor considerations apply

    Autologous HSCT in AML CR1: Auto‑BMT improved disease‑free survival but not overall survival compared with chemotherapy in pooled randomized trials; routine use in CR1 is not supported

    Nathan et al meta‑analysis

    Acute promyelocytic leukemia (APL)

    Covered when ALL of the following are met for APL:

    APL CR1: Stem cell transplantation is not indicated for APL patients in CR1 under contemporary ATRA/ATO‑based risk‑adapted protocols

    Transplant reserved for later remissions or specific MRD‑positive situations

    APL relapsed or refractory: For relapsed/refractory APL, autologous HSCT may be used for patients who achieve prolonged CR2 and are MRD‑negative; allo‑HSCT considered for MRD‑positive or chemotherapy‑resistant disease if a donor is availablein second or subsequent remission and MRD status guides choice

    Evidence favors auto‑HSCT in some CR2 cohorts; allo‑HSCT preferred for MRD‑positive disease

    Chronic and juvenile myelo-monocytic leukemia (CMML/JMML)

    Covered when ALL of the following are met for CMML/JMML:

    CMML/JMML - candidate for allogeneic HSCT: Patients with CMML and JMML may be considered for allogeneic HSCT; outcomes are variable but earlier transplantation and fewer comorbidities are associated with better survival

    Matched or haploidentical donor availability required for some indications

    CMML outcomes and risks: Significant treatment‑related mortality and relapse risk exist (e.g., 5‑year OS ~21% in one series); donor source, graft manipulation, and GVHD influence outcomes

    High TRM reported in several cohorts

    Evidence summaries informing transplant coverage decisions

    Findings that inform transplant candidacy and expected outcomes (not formal authorization criteria in this text selection):

    CMML allogeneic HSCT outcomes: Allogeneic HSCT in CMML can achieve long‑term remissions in subsets of patients but is associated with high treatment‑related mortality and relapse; better outcomes observed in patients with fewer comorbidities and earlier transplant timing

    Kroger, Kerbauy and others report variable OS and high TRM

    JMML: Allogeneic HSCT is the only proven curative therapy for JMML with 5‑year event‑free survival in larger cohorts around 49–55%; younger age and absence of refractory disease at transplant predict better outcomes

    Locatelli and others

    Richter syndrome: Allo‑HCT is a reasonable consolidative option for fit patients with chemo‑sensitive Richter syndrome, with pooled ORR 79% and pooled OS ~49% in limited series; NRM ~24%

    Aulakh systematic review

    Donor selection KIR genotyping: Donor KIR genotype (group B motifs, Cen‑B/B homozygosity, KIR2DL1 alleles) is associated in studies with reduced relapse and improved survival in AML settings; authors suggest inclusion in donor selection algorithms

    Cooley, Bao and others

    Micro‑transplantation can produce anti‑tumor responses even without durable donor engraftment; evidence is emerging particularly in AML but mechanisms and required chimerism thresholds remain undefined

    Dholaria; Cornillon

    Evidence summaries relevant to coverage decisions

    Evidence and considerations relevant to HSCT decisions in selected leukemias:

    Donor KIR genotyping benefits: Donor KIR Bx profile and presence of centromeric B (Cen‑B) motif associated with improved OS and RFS and reduced NRM in standard‑risk AML/MDS in a retrospective cohort; avoid Bx1 donors for standard‑risk AML/MDS in that study population

    Bao et al (210) retrospective cohort; effect not seen in high‑risk AML/MDS or ALL

    Micro‑transplantation (MT): MT can induce anti‑tumor responses without durable donor engraftment via transient micro‑chimerism; data are limited and mostly from Asian cohorts and should be proposed within clinical trials

    Cornillon; Dholaria

    Azacitidine prophylaxis post‑HSCT: Systematic review/meta‑analysis of 444 patients suggests azacitidine after HSCT is associated with 2‑year pooled relapse 25% and 2‑year survival 65% and may be effective for relapse prevention

    Pan et al (2022)

    Consolidative HSCT after CD19 CAR‑T: Meta‑analysis of 690 patients: consolidative HSCT after achieving CR following CD19 CAR‑T improved OS, reduced relapse rate, and improved LFS compared with non‑HSCT; benefits also seen in MRD‑negative CR patients

    Xu et al (2022); pooled AE/incidence estimates provided

    Hepcidin measurement: Systematic review (13 studies) found serum hepcidin elevated in patients with acute leukemia or undergoing HCT; hepcidin may predict worse outcomes but data are heterogeneous and insufficient for practice recommendations

    Slomka et al (2022)

    TKI maintenance vs HSCT in Ph+ ALL: Systematic reviews/meta‑analyses show HSCT followed by TKI may have better relapse outcomes than TKI alone in some analyses, but next‑generation TKIs have improved non‑transplant outcomes such that MRD‑negative patients may have comparable survival without HSCT

    Shahzad et al; Xie et al

    Aetna considers autologous hematopoietic cell transplantation (auto‑HCT) for acute lymphocytic leukemia (ALL) to be experimental/investigational and not covered. This exclusion is based on the policy's assessment that the effectiveness of autologous HCT for ALL has not been established.

    Aetna considers tandem (sequential) transplants for the treatment of ALL to be experimental/investigational and not covered, because available evidence does not establish effectiveness for this approach in ALL.

    Aetna considers a repeat allogeneic hematopoietic cell transplantation (ablative or mini‑allograft) for members with persistent or progressive AML who have not been in remission to be experimental/investigational. The policy indicates insufficient evidence to support repeat allo‑HCT when active disease persists (i.e., not in remission).

    Aetna considers repeat autologous hematopoietic cell transplantation for AML to be experimental/investigational and not covered given lack of established effectiveness for repeat auto‑HCT in this indication.

    The policy lists autologous HCT for chronic myelo‑monocytic leukemia (CMML) and juvenile myelo‑monocytic leukemia (JMML) as experimental/investigational. Evidence summaries for CMML/JMML report variable outcomes and high treatment‑related mortality in some series, and auto‑HCT is not established for routine use in these diseases.

    Hematologic stem cell micro‑transplantation (MT) for AML is considered experimental/investigational. MT techniques (HLA‑mismatched G‑CSF–mobilized cells given with chemotherapy without conditioning or immunosuppression) are investigational because current data are limited, largely from selected cohorts, and insufficient to support routine coverage.

    Measurement of serum hepcidin levels for management of patients with acute leukemia or undergoing hematopoietic cell transplantation (CPT code 0251U) is considered experimental/investigational. The policy indicates that the effectiveness of hepcidin measurement to guide management has not been established.

    For acute promyelocytic leukemia (APL), the policy states that stem cell transplantation is not indicated for patients in first complete remission (CR1) under contemporary ATRA/ATO‑based risk‑adapted protocols. Transplantation is reserved for relapsed/refractory disease or selected later remission scenarios.

    The policy notes that the optimum treatment for juvenile myelomonocytic leukemia (JMML) remains unknown; within the cited studies no clear routine exclusion is provided, and treatment approaches (including consideration of allo‑HCT) are individualized given variable outcomes.

    Micro‑transplantation is described as investigational and the policy recommends that it be proposed within clinical trials because current evidence is insufficient to support routine practice and indications remain undefined.

    The policy indicates that routine use of autologous HSCT for AML in CR1 is not supported; randomized trials and meta‑analysis demonstrated an improvement in disease‑free survival (DFS) without a corresponding overall survival (OS) benefit, so auto‑BMT is not recommended as standard first‑line consolidation for CR1 AML.

    The document does not provide broad, categorical exclusions beyond the specific investigational items listed; instead it emphasizes that outcomes are variable across diseases and series and that candidacy and decisions depend on disease status, donor availability, comorbidity, age, and other factors.

    no persistent disease for mini‑allograft in ALL; remission/response for autologous AML

    Selection based on cytogenetic risk

    Selection frequently depends on cytogenetic risk, age, remission status, and donor availability:

    AML candidate selection by cytogenetics: For AML in CR1, selection for myeloablative allo‑HSCT should be based on cytogenetic risk: recommended for poor‑risk and some intermediate‑risk; not recommended for favorable‑risk

    Koreth et al; Morra et al; Cornelissen et al

    Candidate selection observations

    Clinical characteristics associated with candidacy or better outcomes described in these sections:

    Low comorbidity and earlier transplant: Patients with few or no comorbidities and those who undergo transplantation earlier in the disease course have higher probability of successful outcome after allogeneic HSCT

    Kerbauy et al.; Locatelli et al.

    Chemo‑sensitive disease pre‑HCT for Richter syndrome: Patients with chemo‑sensitive RS disease response prior to procedure are reasonable candidates for allo‑HCT

    Aulakh et al.; guideline citations

    Contraindications called out in the policy include: persistent disease (patients with active, persistent leukemia are contraindicated for non‑myeloablative/mini‑allograft transplants in ALL) and refractory relapse defined as disease unresponsive to adequate chemotherapy for 3 or more months. These conditions exclude patients from transplantation when present, unless exceptional circumstances and selection criteria are met.

    The policy reiterates that persistent disease is a contraindication to non‑myeloablative (mini‑allograft) transplant in ALL and that refractory relapse (unresponsiveness to at least 3 months of adequate chemotherapy) generally precludes allogeneic HCT under the policy's framework.

    High comorbidity burden and advanced age with expected high transplantation‑related mortality (TRM) are noted as potential contraindications or factors that may alter the risk/benefit balance for allogeneic transplant. The policy highlights that elevated TRM in older or high‑risk patients can negate survival benefits observed in fitter populations.

    Evidence cited in the policy shows that patients with higher HSCT‑specific comorbidity scores had worse overall survival after transplant. Accordingly, a high comorbidity burden may be considered a relative contraindication to HSCT in some patients if it predicts unacceptably poor outcomes.

    The policy does not list additional absolute contraindications in the cited excerpts. For investigational approaches such as micro‑transplantation, the policy notes its investigational status and suggests it may be considered for patients ineligible for standard allo‑SCT, typically within clinical trials rather than routine practice.

    • Pre-transplant disease documentation: date and type of last disease assessment, imaging/labs, bone marrow biopsy results
    • MRD documentation: method (PCR/flow), quantitative result and date; document MRD-negative vs MRD-positive status
    • Document CAR-T response: CR vs CR with MRD-negativity and duration of response prior to considering consolidative HSCT
    • Document TKI response: type of TKI, duration of therapy, molecular response within 3 months when relevant (e.g., Ph+ ALL)
    Denial Risk

    Transplant-Related Mortality and Comorbidity Risk

    Coverage decisions for allogeneic HCT are influenced by transplant-related mortality (TRM) risk and comorbidities. High expected TRM or significant comorbidity burden may lead to denial or non-coverage of allogeneic HCT. Providers should include HSCT-specific comorbidity index (HCT-CI), performance status, and organ function testing in submissions.

    • TRM affects coverage decisions — include documented estimates or clinical justification if TRM is elevated
    • Comorbidity-related denial risk: submit HCT-specific comorbidity index and explain how comorbidities are being managed or mitigated
    • Performance status and organ function: ECOG/KPS, cardiac, pulmonary, hepatic, renal evaluations
    Step Therapy

    Therapy Sequencing and Step-Therapy Considerations

    Therapy sequencing and step-therapy considerations should be documented. For certain diseases (e.g., Ph+ ALL), documentation of an adequate trial and response to tyrosine kinase inhibitor (TKI) therapy is expected prior to proceeding to HSCT when guideline-concordant. Consideration of non-transplant consolidation (for example, further systemic therapy or observation) should be noted when applicable.

    • Step therapy: document TKI use and molecular response (CMR) within recommended timeframes (often ~3 months) prior to HSCT consideration
    • Consider non-transplant consolidation before HSCT when guidelines support observation or further consolidation (e.g., certain APL or RS scenarios)
    • Document prior lines of therapy, dates, responses, and rationale for proceeding to transplant vs continued non-transplant management
    Billing Rule

    Authorization Omissions and Common Denial Triggers

    Operational expectations and denial triggers: when prior authorization is not obtained or required elements are missing, coverage may be delayed or denied. This section summarizes provider actions that commonly affect eligibility and adjudication.

    • No explicit authorization: if prior authorization is not obtained where required, claims may be denied or returned for retro-review
    • Denial triggers for allogeneic HCT: inadequate documentation of chemo-sensitivity/response, unacceptable TRM/comorbidity profile, lack of suitable donor documentation, or missing MRD/disease assessments
    • No explicit additional denial triggers are specified within this fragment beyond documentation and medical-necessity considerations
    Note

    Transplant Center and Donor Evaluation Requirements

    Referral to and selection by a transplant center is required to confirm eligibility. The transplanting institution must document its selection criteria and confirm donor compatibility testing (including HLA typing and crossmatch) and infectious disease screening prior to transplant.

    • Center requirements: transplant center selection criteria and attestation of eligibility must be included in the record
    • Donor evaluation: include HLA typing, compatibility testing results, donor infectious disease screening, and donor source/type
    • Prior authorization should reflect whether transplant center acceptance has been obtained
    Note

    Policy History, Evidence, and Citation Expectations

    Policy history and supporting references should be included in the medical record submission when relevant to clinical rationale. Providers should cite guideline sources or recent evidence if relying on non-standard sequencing (for example, use of next-generation TKIs in lieu of HSCT in MRD-negative Ph+ ALL).

    • Include relevant guideline citations (e.g., NCCN, UpToDate) or recent studies supporting the chosen management pathway
    • Document date of last policy review or institutional guideline when used to justify deviation from typical care pathways
    Refractory relapse (policy definition)
    DefinitionRefractory relapse = relapse that is unresponsive to 3 or more months of adequate chemotherapy.
    ContextApplies to determination of medical necessity for allogeneic HCT in ALL; persons in refractory relapse are excluded from coverage for allo‑HCT under this policy.
    Minimum durationThreshold specifies a duration of at least 3 months of adequate chemotherapy to define unresponsiveness.
    Prior Authorization

    Prior authorization required for transplant procedure codes

    Obtain prior authorization for listed transplant‑related CPT/HCPCS codes (for example 38205, 38230, 38240, 86813, 86817, 86821, S2150); coverage is contingent on meeting the policy's selection/medical‑necessity criteria.

    • Prior authorization required for codes: 38205, 38206‑38215, 38230, 38232, 38240, 38241, 38242, 86813, 86817, 86821, 0251U, S2150 (as listed)
    • Provide documentation that selection criteria/medical necessity are met when requesting authorization
    Prior Authorization

    Donor‑ and risk‑stratified authorization: align requests with cytogenetic risk

    Authorization decisions should reflect donor‑ and cytogenetic risk stratification (for example, allo‑HSCT is recommended for poor‑risk and some intermediate‑risk AML in CR1); ensure documentation aligns with risk‑stratified indications.

    • Document cytogenetic risk category and rationale for allo‑HSCT in CR1 when applicable
    • Include donor availability and donor type considerations in authorization materials
    Prior Authorization

    Transplant center evaluation required to confirm eligibility

    Refer members to and obtain evaluation from a transplant center to confirm eligibility; the center evaluation should document organ function, performance status, and donor availability to support authorization.

    • Transplant center must confirm fitness, organ function, and donor suitability
    • Include transplant center evaluation notes with authorization request
    Prior Authorization

    Prior authorization: consolidative HSCT after CD19 CAR‑T — document CR/MRD

    When requesting authorization for consolidative HSCT after CD19 CAR‑T, provide documentation of CR or MRD status because meta‑analysis demonstrated improved overall survival and reduced relapse with consolidative HSCT.

    • Document CR and MRD status following CAR‑T in the prior authorization submission
    • Cite evidence of benefit (meta‑analysis) when applicable to support medical necessity
    Note

    Prior authorization: no additional steps specified here

    This section of the policy does not list additional specific prior authorization steps beyond code‑level authorization and meeting selection criteria; use the listed codes and selection criteria when preparing requests.

    • Follow code list and medical necessity criteria; no other concrete prior authorization steps specified in this fragment
    Documentation Required

    Therapy sequencing: document prior therapies and transplant history

    Document prior lines of therapy and prior autologous transplant status when applicable; coverage considerations reference sequencing (e.g., transplant for relapsed/refractory disease after conventional therapy).

    • List prior systemic therapies, response, and dates
    • Document prior autologous HSCT if applicable
    Step Therapy

    Consider non‑transplant consolidation before HSCT in some AML CR1 patients

    Consider and document use of non‑transplant consolidation (e.g., consolidation chemotherapy) in AML CR1 patients when appropriate; evidence supports reserving transplant based on donor availability and cytogenetic risk.

    • If non‑transplant consolidation chosen, describe rationale and cytogenetic risk to justify alternative to HSCT
    Documentation Required

    Pre‑HCT therapy: document intensified chemotherapy and response in older ALL patients

    For older ALL patients, document prior intensified chemotherapy regimens and response; authorization should include this information when allo‑HCT is being considered after intensified therapy.

    • Include treatment regimens, dates, and response in authorization documentation
    Step Therapy

    Step therapy: document TKI response and MRD before HSCT for Ph+ ALL

    For Ph+ ALL, document response to tyrosine kinase inhibitor (TKI) therapy and MRD status before HSCT authorization, since next‑generation TKIs ± chemotherapy may achieve comparable survival to allo‑HSCT in MRD‑negative patients.

    • Provide molecular response (CMR/MRD) after TKI therapy and duration of response
    • If MRD‑negative after next‑generation TKI, include rationale if HSCT is still being requested
    Note

    Clinical sequencing references: no explicit payer step‑therapy rules

    Clinical publications in the references discuss sequencing (consolidation, transplant after remission) but the policy does not impose specific payer step‑therapy rules beyond documenting prior therapy and response.

    • Clinical citation context provided but no payer step‑therapy mandates stated
    Documentation Required

    Documentation: confirm member meets transplanting institution's selection criteria

    Provide documentation that the member meets the transplanting institution's selection criteria (or applicable Aetna indications) including remission status, prior treatment response, donor availability, and fitness to tolerate the procedure.

    • Include confirmation that institutional selection criteria are met
    • Attach transplant center evaluation or institutional eligibility statement
    Documentation Required

    Pre‑transplant documentation: molecular MRD and prior CR duration (APL example)

    Include molecular MRD results (for example PML‑RARα in APL) and prior complete remission duration in pre‑transplant documentation because these elements affect auto‑ versus allo‑HSCT decisions.

    • Provide RT‑PCR or other molecular assay results (e.g., PML‑RARα) and date
    • Report duration of prior CR(s)
    Documentation Required

    Pre‑transplant documentation: comorbidity index, performance status, organ function

    Document HSCT‑specific comorbidity index, performance status, organ function tests, and demonstration of chemo‑sensitive disease where applicable to support candidacy and authorization.

    • Record HSCT‑specific comorbidity index score and interpretation
    • Provide organ function labs and imaging supporting fitness for transplant
    Documentation Required

    Document CAR‑T response (CR/MRD) for consolidative HSCT requests

    When consolidative HSCT is being considered after CD19 CAR‑T, document prior CAR‑T response status (CR or MRD‑negative CR) because outcomes differ by response and this information supports authorization.

    • Provide CR status and MRD results following CAR‑T in the authorization packet
    Denial Risk

    Denial risk: missing institution selection criteria for ALL allogeneic HCT

    Allogeneic HCT for ALL is medically necessary only when members meet the transplanting institution's selection criteria (or, absent institutional criteria, not in refractory relapse); absence of documentation meeting these criteria may lead to denial.

    • Refractory relapse is defined as relapse unresponsive to ≥3 months of adequate chemotherapy — absence of evidence of meeting selection criteria risks non‑approval
    Denial Risk

    Denial risk: high TRM may negate benefit in older/high‑risk patients

    Be aware that high transplant‑related mortality (TRM) in older or high‑risk patients can abrogate survival benefit; lack of documentation addressing TRM risk and expected benefit may influence coverage decisions.

    • Provide risk/benefit discussion and justification when TRM risk is elevated (e.g., older/high‑risk patients)
    Denial Risk

    Denial risk: high comorbidity increases risk of poor outcomes and possible non‑approval

    Document comorbidity burden using an HSCT‑specific comorbidity index because higher comorbidity scores are associated with worse overall survival after HSCT; absence of fitness documentation may increase risk of denial.

    • Include HSCT comorbidity index score and explanation in authorization materials
    Note

    Authorization context: background evidence only, no explicit authorization steps

    This background evidence section does not specify further authorization requirements; it provides contextual evidence and guideline citations only.

    • Use cited evidence to inform clinical justification but follow code‑level and selection‑criteria requirements for authorization
    Note

    Administrative note: no denial triggers in policy history section

    This administrative section contains policy history and notices and does not list denial triggers or provider action requirements.

    • Policy last review date and effective date are administrative details
    Note
    Key definition: unresponsive to 3 or more months of adequate chemotherapy
    Exact policy phrase"unresponsive to 3 or more months of adequate chemotherapy" — used to define refractory relapse for coverage decisions.
    Use in coverage logicThis phrase is the threshold for excluding members in refractory relapse from allogeneic HCT coverage for ALL when institution selection criteria are absent.
    Implication for documentationProvider documentation should demonstrate duration and adequacy of prior chemotherapy to support or refute refractory relapse status.
    Risk statementSecond allo-HSCT carries high treatment-related mortality and relapse rates; benefits limited to selected patients.
    Post-transplant outcomes and complications (reported findings)
    Reported outcomesPost-transplant outcomes reported include non-relapse mortality (NRM), relapse incidence, and rates of acute/chronic GVHD across cohorts.
    No explicit coverage durationsThese background sections report outcomes and complications but do not specify post-transplant coverage durations or explicit post-transplant coverage rules.
    Example dataIn CMML series, 5-year estimated OS ~21% with 52% treatment-related mortality in one cohort.
    Azacitidine as post‑HSCT prophylaxis (evidence summary)
    Intervention studiedAzacitidine (AZA) as post‑HSCT maintenance/prophylaxis to prevent relapse in myeloid malignancies.
    Pooled outcomes (2 years)Pooled 2‑year cumulative relapse ~25% and 2‑year survival ~65% (meta-analysis of 444 patients).
    Safety/complicationsPooled 2‑year estimates included relapse‑related mortality and acute/chronic GVHD incidence reported in the analysis.
    Micro‑transplantation evidence:
    Micro‑transplantation shows preliminary anti‑tumor activity without durable engraftment; evidence insufficient for routine recommendation and is investigational

    Dholaria; Cornillon

    Evidence summaries relevant to coverage decisions

    Duplicate evidence context to ensure Background includes considerations relevant to HSCT decisions in selected leukemias:

    Azacitidine post‑HSCT evidence: Meta‑analysis suggests azacitidine prophylaxis post‑HSCT is associated with pooled 2‑year relapse 25% and 2‑year survival 65%, informing post‑transplant relapse‑prevention considerations

    Pan et al (2022)

    Consolidative HSCT after CAR‑T evidence: Meta‑analysis of 690 patients indicates consolidative HSCT after CR from CD19 CAR‑T improves OS and reduces relapse compared with no HSCT

    Xu et al (2022)

    Hepcidin and investigational tests: Serum hepcidin measurement is investigational for management of acute leukemia or HCT patients due to heterogeneous evidence and is not recommended for routine use

    Slomka et al (2022)

    Leukemia subtype reference lists
    Reference collectionsPolicy provides indexed reference lists for leukemia subtypes including ALL, AML, CMML/JMML, APL, and Richter syndrome.
    PurposeReferences support evidence summaries and transplant considerations for each subtype.
    Examples of sourcesReferences include randomized trials, meta-analyses, systematic reviews, and society statements cited by subsection (see policy reference list).
    ApplicabilityUsed to expand allo‑HCT candidacy to older or higher‑risk patients when disease is chemo‑sensitive and selection criteria are met.
    Acute myelogenous leukemia (AML)
    DefinitionAcute myelogenous leukemia (AML) = a clonal disease of myeloid progenitors causing accumulation of blasts in marrow and blood leading to marrow failure; incidence increases with age and prognosis depends on age and adverse biologic features.
    Clinical noteAllo‑HSCT is an important option for high‑risk AML in CR1 and for patients in second or subsequent remission.
    Therapy contextReduced‑intensity conditioning has widened allo‑HSCT applicability to more patients.
    Acute promyelocytic leukemia (APL)
    DefinitionAcute promyelocytic leukemia (APL) = a subtype of AML characterized by high responsiveness to all‑trans‑retinoic acid (ATRA) and arsenic trioxide (ATO) with high CR and cure rates under risk‑adapted protocols.
    Treatment noteStem cell transplantation is not indicated for APL patients in first complete remission under contemporary ATRA/ATO‑based protocols.
    Role of HSCTAuto‑ or allo‑HSCT may be considered as consolidation in second or subsequent remission or in relapsed/refractory APL per cited reviews.
    Micro‑transplantation (term)
    TermMicro‑transplantation (MT)
    ConceptTumor responses occurring despite little or no durable donor engraftment; termed micro‑transplantation when anti‑tumor effect occurs without high levels of donor persistence.
    Evidence statusData are limited, mostly from Asian cohorts; MT remains investigational and is proposed to be performed within clinical trials.
    Micro‑transplantation (procedural definition)
    Procedure definitionMicro‑transplantation (MT) = injection of HLA‑mismatched G‑CSF–mobilized hematopoietic stem cells with chemotherapy but without conditioning regimen or post‑transplant immunosuppression, producing transient micro‑chimerism.
    MechanismEfficacy proposed to rely on host immune stimulation and graft‑versus‑tumor effects despite lack of durable engraftment.
    RecommendationCurrent data insufficient for routine recommendations; MT should be proposed within clinical trials per policy references.
    Consolidative HSCT after CD19 CAR‑T
    DefinitionConsolidative HSCT after CD19 CAR‑T = allogeneic hematopoietic stem cell transplant performed after achieving CR (including MRD‑negative CR) following CD19 CAR‑T therapy to reduce relapse and improve survival.
    EvidenceMeta‑analysis of 690 patients showed consolidative HSCT after CR post‑CAR‑T improved OS, reduced relapse, and improved LFS compared with non‑HSCT.
    DocumentationPolicy recommends documenting CR or MRD status when considering consolidative HSCT after CAR‑T to support coverage decisions.
    Leukemia subtype reference lists (index of referenced literature)
    Indexed referencesComprehensive reference lists provided for leukemia subtypes to support background evidence (ALL, AML, CMML/JMML, APL, Richter syndrome).
    ContentsIncludes peer‑reviewed studies, systematic reviews, meta‑analyses, and society statements cited in the policy subsections.
    PurposeReferences inform transplant indications, expected outcomes, and background evidence rather than specifying procedural rules.